TP53 and cancer: Esfandiari et al. recently reported a similar finding [26], in which GSK2830371 potentiated sensitivities to MDM2 inhibitors in p53 wild-type cancer cell lines harboring either PPM1D copy number gains/elevated expression or gain-of-function truncating mutations.